1 / 25

National Institute of Allergy and Infectious Diseases, NIH

Medical Diagnostics NIAID Funding Opportunities Maria Y. Giovanni, Ph.D. Assistant Director for Microbial Genomics and Advanced Technologies National Institute of Allergy & Infectious Diseases Department of Health and Human Services July 14, 2003.

manning
Télécharger la présentation

National Institute of Allergy and Infectious Diseases, NIH

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Medical DiagnosticsNIAID Funding OpportunitiesMaria Y. Giovanni, Ph.D.Assistant Director for Microbial Genomics and Advanced TechnologiesNational Institute of Allergy & Infectious DiseasesDepartment of Health and Human ServicesJuly 14, 2003

  2. National Institute of Allergy and Infectious Diseases, NIH Mission Supports basic and applied research to prevent, diagnose and treat infectious and immune-mediated illness, including HIV/AIDS, and other sexually transmitted diseases, illness from potential agents of bioterrorism, tuberculosis, malaria, autoimmune disorders, asthma and allergies.

  3. NIAID Medical Diagnostics • Identify infectious agents in clinical samples including SARS coronavirus, NIAID Category A, B, C agents, other infectious agents, genetically engineered or manipulated organisms and toxins • Rapid, highly sensitive, specific, easy to use and interpret, reliable, multi-plexed, and cost effective medical diagnostics for public health laboratories or point-of-care agents or their toxins. • Identify early infection or exposure for early detection and intervention • Identify/distinguish the agent from common infections • Fully integrated systems from front end sample preparation to molecular detection systems with data acquisition and analysis.

  4. Medical Diagnostics Emerging, Innovative Technologies Dev Technologies Early Stage Product Dev Technologies Later Stage Product /Platform Dev/Validation R Platform Cooperative Initiative Partnership Initiative SBIR/STTR Early Diagnosis/Pre-Symptomatic Pathogen/Host Monitoring Infection and Treatment Pathogen/Host

  5. NIH/NIAID • Support basic and applied research by peer-reviewed grants and contracts to public or private institutions and for-profit and non-profit organizations • Two approaches • Investigator-initiated grants • Targeted initiatives supporting both grants and contracts-PA, RFA, RFP • Allows support for diverse research projects

  6. NIAID Cooperative Research Program for Biodefense & SARS Goal Support research projects that will advance the development a product in a cooperative program with NIAID - Vaccines - Adjuvants - Therapeutics - Diagnostics - Resources

  7. NIAID Biodefense & SARS Partnerships Goal Assist private sector in further development of high priority products for biodefense in a cooperative program with NIAID - Vaccines - Adjuvants - Therapeutics - Diagnostics - Resources

  8. NIAID Small Business Biodefense Grant Program Goal To support Small Business Innovation Research and Small Business Technology Transfer Research grants to stimulate technological innovations to develop: - Vaccines - Adjuvants - Therapeutics - Diagnostics - Resources

  9. Microbial Sequencing Centers Genomic Data Bioinformatics Centers Data Warehouse Data Analysis PFGRC Resources Reagents Proteomic Centers Early Target Ident. HT-Cloning/Expression Basic Research Strain Identification Molecular Genotyping Microbial Biology Pathogenesis Host Response Human Genetic Variations Diagnostics Tech.Dev. Early Identification of Targets Vaccines, Drugs and Target Identification

  10. NIAID Microbial Genome Sequencing Centers Goal: Rapid and cost efficient production of high quality genome sequences of human pathogens and invertebrate vectors of diseases Features: • NIAID-supported Contract Sequencing Facility • Capacity to sequence genomes for: • Scientific community • Responding to national needs • Other government agencies • Anticipated Funding: Late 2003

  11. NIAID Pathogen Functional Genomics Resource Center Goal: Develop and distribute technologies and resources for functional analysis of pathogens at whole genome or whole cell/organism level

  12. NIAID Pathogen Functional Genomics Resource Center Genomic Resources Provided: • cDNA microarrays • Genetic Variation/SNP analysis • Develop computational tools for array and comparative genomic data analysis • Web site • Distribute organism-specific arrays and protocols to scientific community • Provide reagents-microbial strains, clones or isolates, libraries, PCR primers

  13. NIAID Bioinformatics Resource Centers Goal: Provide the Scientific Community with a robust point of entry for access of genomic and related data in a user-friendly format. Components - Database • Genomic and Related Data - Analysis Center • Develop and Provide Software Tools - Multi-disciplinary Team • Bioinformatics and Database Experts and Organism-Specific Biologists

  14. NIAID Proteomics Initiative Title: Biodefense and Emerging And Re-emerging Proteomics Research Programs: Identifying Targets for Therapeutic Interventions Using Proteomic Technology Goal: Characterize the pathogen and/or host cell proteome, identifying proteins associated with biology of microbes, mechanisms of microbial pathogenesis, and host response to infection with the goal of discovering targets for potential candidates for the next generation of vaccines, therapeutics, and diagnostics.

More Related